Evidence map›Paper›PMID 42270782›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026

Effort, timing and choice: a refined rodent effort choice task with excellent sensitivity to dopamine modulators.

Suellen Almeida-Correa, Fynn-Sebastian Wesemann, Sarah Diez, Mary Jane Maynard, Lucas Yebra Garcia, Patrizia Voehringer, Boris Ferger, Michael Becker, Carsten T Wotjak, Johann du Hoffmann

Abstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Suellen Almeida-CorreaNeuroscience and Mental Health Discovery Research Department, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.ORCID http://orcid.org/0000-0002-5876-7971
Fynn-Sebastian WesemannNeuroscience and Mental Health Discovery Research Department, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Sarah DiezNeuroscience and Mental Health Discovery Research Department, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Mary Jane MaynardNeuroscience and Mental Health Discovery Research Department, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Lucas Yebra GarciaNeuroscience and Mental Health Discovery Research Department, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Patrizia VoehringerNeuroscience and Mental Health Discovery Research Department, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Boris FergerNeuroscience and Mental Health Discovery Research Department, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Michael BeckerDrug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Carsten T WotjakNeuroscience and Mental Health Discovery Research Department, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.ORCID http://orcid.org/0000-0002-2159-5379
Johann du HoffmannNeuroscience and Mental Health Discovery Research Department, Boehringer Ingelheim Pharma GmbH, Biberach, Germany. johann_faustus.du_hoffmann@boehringer-ingelheim.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Motivational deficits and anhedonia are core features of psychiatric disorders such as depression, schizophrenia and addiction, yet current treatments rarely improve these symptoms. Progress towards targeted therapeutics requires preclinical tasks that reliably capture pharmacological modulation of relevant neural circuits. Here, we developed a modified effort-related choice task (mERC) that integrates high effort demands, extended intertrial intervals and choice, to enable robust bidirectional sensitivity to systemic pharmacology. Unlike standard paradigms, mERC detects both impairing and enhancing effects of dopamine modulators within a single task and reveals drug-sensitive anticipatory responses during intertrial intervals-a behavioral feature linked to interval timing and motivational vigor. Using neurochemical and photometric analyses, we show that mERC performance is associated with behavioral signatures consistent with dopaminergic signaling across different timescales and is potentially constrained by a bounded dynamic range beyond which behavioral modulation is lost. Species differences in drug efficacy map onto baseline dopamine tone and depletion dynamics, underscoring the interactions between task structure and neurochemical state. Together, these findings establish mERC as a stable and sensitive preclinical assay for enhancing our understanding of effort-based decision-making and for screening novel therapeutics targeting motivational dysfunction.

Indexed as

Choice BehaviorDopamineDopamine AgentsMotivationAnimalsMaleRatsTime FactorsDopamineDopamine Agents

Identifiers

PMID42270782
PMCPMC13597516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.